Insufficient blood vessel supply is a primary limiting factor for regenerative approaches to large bone defect repair. Recombinant bone morphogenetic protein-2 (BMP-2) delivery induces robust bone formation and has been observed to enhance neovascularization, but whether the angiogenic effects of BMP-2 are due to direct endothelial cell stimulation or due to indirect paracrine signaling remain unclear. In this study, we evaluated the effects of BMP-2 delivery on vascularized bone regeneration and tested whether BMP-2 induces neovascularization directly or indirectly. We found that delivery of BMP-2 (5 μg) enhanced both bone formation and neovascularization in critically sized (8 mm) rat femoral bone defects; however, BMP-2 did not directly stimulate angiogenesis in vitro. In contrast, conditioned medium from both mesenchymal progenitor cells and osteoblasts induced endothelial cell migration in vitro, suggesting a paracrine mechanism of BMP-2 action. Consistent with this inference, codelivery of BMP-2 with endothelial colony forming cells to a heterotopic site, distant from the skeletal stem cell-rich bone marrow niche, induced ossification but had no effect on neovascularization. Taken together, these data suggest that paracrine activation of osteoprogenitor cells is an important contributor to neovascularization during BMP-2-mediated bone regeneration.
Impact Statement
In this study, we show that bone morphogenetic protein-2 (BMP-2) robustly induces neovascularization during tissue-engineered large bone defect regeneration, and we found that BMP-2 induced angiogenesis, in part, through paracrine signaling from osteoprogenitor cells.
Get full access to this article
View all access options for this article.
References
1.
DesaiB.Osteobiologics. Am J Orthop (Belle Mead NJ), 36, 8, 2007.
2.
KannanR.Y., SalacinskiH.J., SalesK., ButlerP., and SeifalianA.M.The roles of tissue engineering and vascularisation in the development of micro-vascular networks: a review. Biomaterials, 26, 1857, 2005.
3.
USBJI. United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States (BMUS). United States Bone and Joint Initiative, 2014.
4.
EhrlerD., and VaccaroA.The use of allograft bone in lumbar spine surgery. Clin Orthop Relat Res, 371, 38, 2000.
5.
FlierlM.A., SmithW.R., MauffreyC., et al.Outcomes and complication rates of different bone grafting modalities in long bone fracture nonunions: a retrospective cohort study in 182 patients. J Orthop Surg Res, 8, 33, 2013.
6.
GarrisonK.R., DonellS., RyderJ., et al.Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess, 11, 1, iii, 2007.
7.
DahabrehZ., CaloriG.M., KanakarisN.K., NikolaouV.S., and GiannoudisP.V.A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic protein-7. Int Orthop, 33, 1407, 2009.
8.
KanakarisN.K., PaliobeisC., NlanidakisN., and GiannoudisP.V.Biological enhancement of tibial diaphyseal aseptic non-unions: the efficacy of autologous bone grafting, BMPs and reaming by-products. Injury, 38S, S65, 2007.
9.
SenM.K., and MiclauT.Autologous iliac crest bone graft: should it still be the gold standard for treating nonunions? Injury, 38, 2, 2007.
10.
PhelpsE.A., and GarcíaA.J.Engineering more than a cell: vascularization strategies in tissue engineering. Curr Opin Biotechnol, 21, 704, 2010.
11.
BoerckelJ.D., UhrigB.A, WillettN.J., HuebschN., and GuldbergR.E.Mechanical regulation of vascular growth and tissue regeneration in vivo. Proc Natl Acad Sci U S A, 108, E674, 2011.
12.
RaidaM., HeymannAC., GüntherC., and NiederwieserD.Role of bone morphogenetic protein 2 in the crosstalk between endothelial progenitor cells and mesenchymal stem cells. Int J Mol Med, 18, 735, 2006.
13.
FinkenzellerG., HagerS., and StarkG.B.Effects of bone morphogenetic protein 2 on human umbilical vein endothelial cells. Microvasc Res, 84, 81, 2012.
14.
DeckersM.M., van BezooijenR.L., van der HorstG., et al.Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology, 143, 1545, 2002.
15.
de Jesus PerezV.A., AlastaloJ.C., WuJ.D., et al.Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol, 184, 83, 2009.
16.
LangenfeldE.M., and LangenfeldJ.Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res, 2, 141, 2004.
17.
BoerckelJ.D., DupontK.M., KolambkarY.M., LinA.S.P., and GuldbergR.E.In vivo model for evaluating the effects of mechanical stimulation on tissue-engineered bone repair. J Biomech Eng, 131, 084502, 2009.
18.
BoerckelJ.D., ChandrasekharanU.M., WaitkusM.S., et al.Mitogen-activated protein kinase phosphatase-1 promotes neovascularization and angiogenic gene expression. Arterioscler Thromb Vasc Biol, 34, 1020, 2014.
19.
IngramD.A., MeadL.E., TanakaH., et al.Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood, 104, 2752, 2004.
20.
IngramD.A., MeadL.E., MooreD.B., et al.Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood, 105, 2783, 2005.
21.
MasonD.E., CollinsJ.M., DawahareJ.H., et al.YAP and TAZ limit cytoskeletal and focal adhesion maturation to enable persistent cell motility. J Cell Biol, 218, 1369, 2019.
22.
SchindelinJ., Arganda-CarrerasI., FriseE., et al.Fiji: an open-source platform for biological-image analysis. Nat Methods, 9, 676, 2012.
23.
ChittetiB.R., ShivdasaniR.A., WilsonK., et al.Osteoblast lineage cells expressing high levels of Runx2 enhance hematopoietic progenitor cell proliferation and function. J Cell Biochem, 111, 284, 2010.
24.
KacenaM.A., ChengY.-H., StreicherD.A., et al.Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res, 19, 652, 2004.
25.
ChittetiB.R., KacenaM.A., Voytik-HarbinS.L., and SrourE.F.Modulation of hematopoietic progenitor cell fate in vitro by varying collagen oligomer matrix stiffness in the presence or absence of osteoblasts. J Immunol Methods, 425, 108, 2015.
26.
KegelmanC.D., MasonD.E., DawahareJ.H., et al.Skeletal cell YAP and TAZ combinatorially promote bone development. FASEB J, 32, 2706, 2018.
SampathT.K., MaliakalJ.C., HauschkaP.V., et al.Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem, 267, 20352, 1992.
29.
WozneyJ.M.Overview of bone morphogenetic proteins. Spine (Phila Pa 1976), 27, S2, 2002.
30.
CaoL., WangJ., HouJ., XingW.and Liu, C. Vascularization and bone regeneration in a critical sized defect using 2-N,6-O-sulfated chitosan nanoparticles incorporating BMP-2. Biomaterials, 35, 684, 2014.
31.
StewartR.L., GoldsteinJ., EberhardtA., ChuT.-M.G., and GilbertS.Increasing vascularity to improve healing of segmental defect of the rat femur. J Orthop Trauma, 25, 472, 2011.
32.
KempenD.H.R., LuL., HeijinkA., et al.Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials, 30, 2816, 2009.
33.
RothhammerT., BatailleF., SprussT., EissnerG., and BosserhoffA.-K.Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene, 26, 4158, 2007.
34.
DyerL.A., PiX., and PattersonC.The role of BMPs in endothelial cell function and dysfunction. Trends Endocrinol Metab, 25, 472, 2014.
35.
GlienkeJ., SchmittO., PilarskyC., et al.Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem, 267, 2820, 2000.
36.
LinY., WeisdorfD.J., SoloveyA., and HebbelR.P.Origins of circulating endothelial cells and endothelial outgrowth from blood. [Miscellaneous Article] 39. J Clin Invest, 105, 71, 2000.
37.
AsaharaT., MasudaH., TakahashiT., et al.Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res, 85, 221, 1999.
38.
PatelC.V.Endothelial cells express a novel, tumor necrosis factor-alpha-regulated variant of HOXA9. J Biol Chem, 274, 1415, 1999.
39.
YoderM.C., MeadL.E., PraterD., et al.Plenary paper redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood, 109, 1801, 2007.
40.
LinR.-Z., Moreno-LunaR., LiD., et al.Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad Sci, 111, 10137, 2014.
41.
Melero-MartinJ.M., De ObaldiaM.E., KangS.-Y., et al.Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res, 103, 194, 2008.
42.
BaratiD., ShariatiS.R.P., MoeinzadehJ., et al.Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming cells co-encapsulated in a patterned hydrogel. J Control Release, 223, 126, 2016.
43.
MatsubaraH., HoganD.E., MorganE.F., et al.Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis. Bone, 51, 168, 2012.
44.
BeamerB., HettrichC., and LaneJ.Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing. HSS J, 6, 85, 2010.
45.
MoriS., YoshikawaH., HashimotoJ., et al.Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone, 22, 99, 1998.
46.
BragdonB., LamS., AlyS., et al.Earliest phases of chondrogenesis are dependent upon angiogenesis during ectopic bone formation in mice. Bone, 101, 49, 2017.
47.
BoerckelJ.D., KolambkarY.M., DupontK.M., et al.Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials, 32, 5241, 2011.
48.
SantosM.I., and ReisR.L.Vascularization in bone tissue engineering: physiology, current strategies, major hurdles and future challenges. Macromol Biosci, 10, 12, 2010.
49.
SantoV.E., GomesM.E., ManoJ.F., and ReisR.L.Controlled release strategies for bone, cartilage, and osteochondral engineering—part II: challenges on the evolution from single to multiple bioactive factor delivery. Tissue Eng Part B Rev, 19, 327, 2013.
50.
ChengH., JiangW., PhillipsF.M., et al.Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am, 85–A, 1544, 2003.
51.
LeeK.-S., KimH.-J., LiQ.-L., et al.Runx2 is a common target of transforming growth factor beta 1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol, 20, 8783, 2000.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
